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Abstract
Background: Plant biotechnology provides a valuable contribution to global health, in part because it can decrease the cost
of pharmaceutical products. Breast cancer can now be successfully treated by a humanized monoclonal antibody (mAb),
trastuzumab (Herceptin). A course of treatment, however, is expensive and requires repeated administrations of the mAb.
Here we used an Agrobacterium-mediated transient expression system to produce trastuzumab in plant cells.
Methodology/Principal Findings: We describe the cloning and expression of gene constructs in Nicotiana benthamiana
plants using intron-optimized Tobacco mosaic virus- and Potato virus X-based vectors encoding, respectively, the heavy and
light chains of trastuzumab. Full-size antibodies extracted and purified from plant tissues were tested for functionality and
specificity by (i) binding to HER2/neu on the surface of a human mammary gland adenocarcinoma cell line, SK-BR-3, in
fluorescence-activated cell sorting assay and (ii) testing the in vitro and in vivo inhibition of HER-2-expressing cancer cell
proliferation. We show that plant-made trastuzumab (PMT) bound to the Her2/neu oncoprotein of SK-BR-3 cells and
efficiently inhibited SK-BR-3 cell proliferation. Furthermore, mouse intraperitoneal PMT administration retarded the growth
of xenografted tumors derived from human ovarian cancer SKOV3 Her2+ cells.
Conclusions/Significance: We conclude that PMT is active in suppression of cell proliferation and tumor growth.
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Introduction
There was a time when most medicinal compounds were simply
extracted from plants, but now, plant molecular biology produces
valuable recombinant pharmaceutical molecules, including en-
zymes, vaccines, and antibodies [1–9]. Such ‘‘molecular farming’’
has many economic and qualitative benefits, including reduced
health risks from human and animal pathogen contamination and
comparatively high yields. It has been estimated that the cost of
pharmaceutical protein production in plants could be 10- to 50-
fold lower than production of the same protein in mammals
[10,11]. Plants rapidly accumulate single-chain [12–15] and full-
size antibodies [16–20] and may produce personalised patient-
specific anticancer vaccines [21]. Plants may be a source of
biosimilars, new versions of known pharmaceuticals, including
anticancer antibodies [22].
Human epidermal growth factor receptor 2 (HER2/neu) is an
oncogene involved in abnormal cell growth in breast cancer and is a
target for the humanised monoclonal antibody (mAb) trastuzumab
(Herceptin) [23], which was approved by the US Food and Drug
Administration for the treatment of HER2/neu-overexpressing
breast tumours. HER2/neu is overexpressed in 20–30% of
metastatic breast cancer patients where its overexpression results
in the disruption of normal signaling pathways, causing the loss of
cell growth regulation and the development of resistance to
apoptosis. Trastuzumab induces antibody-dependent cellular cyto-
toxicity (ADCC), inhibits HER2-mediated signaling, and prevents
cleavage of the extracellular domain of HER2 [24]. In HER2-
positive breast cancer, trastuzumab has shown a survival advantage
in early and metastatic disease and is now the standard of care [25–
27]. Trastuzumab is produced by recombinant DNA technology in
a mammalian cell (Chinese Hamster Ovary) culture. Recently, the
production of plant-made trastuzumab [PMT] was shown in plant
using the magnICON viral-based transient expression system [19].
Functional assays revealed that plant-produced trastuzumab and
Herceptin have similar antiproliferative effects in vitro on HER2+
breast cancer cells.
Here, we used also genes encoding both heavy and light chains
of trastuzumab, cloned into 35S- and virus-based vectors and
expressed in Nicotiana benthamiana leaves. We show that both vector
systems result in high yield of full-size antibodies, PMT, which
recognizes HER2/neu on the surface of a human mammary gland
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17541adenocarcinoma cell line, SK-BR-3, and active in suppression of
cell proliferation in vitro. Moreover, mouse PMT administration
retarded efficiently the growth of xenografted Her2+ human
ovarian tumors.
Results
Accumulation and purification of assembled PMT in N.
benthamiana leaves
To prove the applicability of our plant transient system for the
production of anticancer mAb, we synthesized genes encoding the
heavy and light chains of the trastuzumab protein using the amino
acid sequence published in DrugBank (accession number
DB00072) and constructed 35S-based vectors (35S-LC and 35S-
HC) (Figure 1A). N. benthamiana leaves co-agroinjected with PT-
LC, PT-HC and the silencing suppressor Tomato Bushy Stunt Virus
(TBSV) p19 [28] produced a high yield of PMT, as revealed in a
gel stained with Coomassie blue. Assembled antibodies were
extracted from plant tissue, purified on protein A affinity columns,
and analyzed either by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) under reducing conditions followed
by Coomassie blue staining (Figure 1B) or by western blotting
probed with gamma-HC- and kappa-LC-specific antibodies
(Figure 1C,D). Bands corresponding to the heavy chain
(,55 kDa) and the light chain (,25 kDa) are clearly visible on
the Coomassie-stained gel (Figure 1B) and on western blots
(Figure 1C, D). Expression of 35S-based constructs was maximal
at 3 dpi, and the yield was between 100 and 150 mg/g of fresh
weight (FW), depending on the experiment.
Next, PMT light and heavy chain genes were cloned into PVX-
based and TMV-based vectors, respectively (Figure 2A), as these
vectors are able to replicate within the same cell with high
efficiency and do not compete with each other for replication
binding sites [17]. Fully assembled PMT was extracted from N.
benthamiana leaves co-injected with HC-TMV and LC-PVX
vectors at 7 dpi when the maximal level of antibody production
was detected (data not shown). Antibodies were purified on protein
A sepharose columns and analyzed via SDS-PAGE under non-
reducing (Figure S1A) or reducing (Figure S1B) conditions.
MALDI-TOF analysis showed an identical peptide composition
of PMT and trastuzumab light and heavy chains (data not shown).
Assembled PMT is detected on gels stained with Coomassie blue.
Western blot analysis was performed to determine the composition
of the other bands on the gel. Probing with anti-gamma-chain
antibodies revealed two high molecular weight bands, also
detected with anti-kappa-chain antibodies (Figure 2B,C), that
likely represent fully assembled IgG molecules and heterotrimers
[(HC)2+LC]. The band that corresponds to the monomeric heavy
chain is also visible in Figure 2B. Of these forms, the
heterotetramer [(HC)2+(LC)2] is the most intense band visible
after Coomassie blue staining (Figure S1B). Another band
(,95 kDa) detected on both 2B and 2C western blots appears to
be a heterodimer of heavy and light chains. In addition, a strong
band most likely corresponding to the dimeric form of the light
chain (,43 kDa) was produced with anti-kappa-chain antibodies.
After treatment with 2-mercaptoethanol, all additional bands
disappeared, with only heavy (Figure 2D) and light chains
(Figure 2E) present. The yield of PMT expressed from viral
vectors was between 200 and 300 mg/g FW depending on the
experiment.
Further PMT purification on an AKTApurifier (GE Health-
care) was used to obtain assembled PMT that was free of
additional complexes between heavy and light chains (Figure S2).
Figure 2F shows capillary electrophoresis of PMT performed on
an Agilent 2100 Bioanalyzer under reducing conditions, where
peak 12 corresponds to HC and peak 8 corresponds to LC. It is
likely that peaks 2 and 3 are low molecular products of PMT
degradation.
Direct comparison of PMT and trastuzumab revealed a similar
protein profile on gels stained with Coomassie blue (Figure 2G, H)
and the absence of visible contaminations on HPLC trace analysis
(Figure 2I).
PMT recognises a HER2/neu peptide mimotope
Trastuzumab binds amino acids 579 to 625 at the C-terminal
end of domain IV of the extracellular region of HER2 [29].
Recently, the conformational epitope 563 to 598 of engineered
trastuzumab demonstrated antitumour activity against HER-2/
neu [30]. To examine whether PMT may bind the trastuzumab
conformational epitope 563 to 598 we synthesised a cyclic
synthetic peptide, 563CYC [29,30] and compared PMT and
trastuzumab binding by ELISA. Polystyrene plates were coated
overnight with the 563CYC peptide and probed with PMT and
trastuzumab the following day. Figure 3 shows that both mAbs,
PMT and trastuzumab, bind the synthetic peptide 563CYC in a
dose-dependent manner.
PMT binds efficiently to HER2/neu-expressing SK-BR-3
cells
For quantitative estimation of the binding affinity of PMT to
Her2/neu antigen displayed on cells, FACS analysis was
performed. Figure 4 (D–F) shows a high percentage (75.7% to
98.3%) of PMT binding to surface HER2/neu independently of
antibody concentration. This result is similar to the data obtained
using trastuzumab (Figure 4A–C).
Figure 1. Production of assembled PMT in N. benthamiana
leaves co-injected with 35S-based light- and heavy-chain-
expressing vectors. A – Schematic representation of 35S-based
light- (LC) and heavy-(HC) chain- expressing vectors 35S-LC and 35S-HC,
respectively. 35S – Cauliflower mosaic virus 35S promoter, T –
terminator of transcription, RB and LB – right and left borders from
Ti-plasmid. B – Coomassie blue-stained SDS-PAGE proteins before
purification (lane 1) and eluted fractions (3–11) obtained after protein A
affinity chromatography, lane 2 – flow through after the first loading on
the protein A column. M, molecular weight markers. C, D - Western blot
analysis of PMT under reducing conditions, developed with anti-gamma
(C) and -kappa (D)-chain-specific antibodies.
doi:10.1371/journal.pone.0017541.g001
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gland adenocarcinoma cell line that overexpresses HER2/neu,
SK-BR-3, was performed to test the functional activity of the
plant-made mAb. PMT bound to Her2/neu oncoprotein on the
surface of these cells as effectively as the diagnostic antibody
A0485 (Dako, Denmark) (data not shown). The same result was
obtained on tissue samples from a patient with Her2/neu-positive
cancer (data not shown).
We conclude that PMT and trastuzumab exhibit no difference
in binding capacity for HER2/neu.
PMT inhibits SK-BR-3 cell growth in vitro
The SK-BR-3 cell line was used to compare the antiproliferative
properties of PMT and trastuzumab. Varying concentrations of
PMT (0.1–1.0 mg/ml) were added to cell cultures, and their
effects on cell growth were assessed in triplicate MTT assays. The
data presented in Figure 5 show similar inhibitory effects of PMT
and trastuzumab on SK-BR-3 cell proliferation. We conclude that
PMT possesses the anticancer properties of trastuzumab.
PMT retards SKOV3-derived tumor growth in a xenograft
mouse model of human ovarian cancer
Having shown that PMT suppresses tumor cell growth, we
investigated its antitumor effects in SKOV3 Her2+ cells implanted
into mice. Although it is known that SKOV3-derived tumors are
less sensitive to trastuzumab than are SK-BR-3-derived tumors
[31], this model reveals the antitumor activity of PMT.
As shown in Figure 6, PMT treatment caused a delay in tumor
growth. After 8 consecutive injections (10 mg/kg, see Material and
M e t h o d s ) ,t h er e d u c t i o ni nt u m o rg r owth was 70% compared to control
mice treated with saline solution. Ten days after the last administration
of PMT, there was an overall 80% reduction in tumor growth.
Trastuzumab injections demonstrated a low effect on tumor growth.
We conclude that PMT possesses the major antitumor activity.
Figure 2. Accumulation and purification of assembled PMT in N. benthamiana leaves co-injected with light-chain-encoding PVX-
based and heavy-chain-encoding TMV-based vectors. A – Schematic representation of PVX- and crTMV-based vectors. LB and RB, binary
vector left and right borders, respectively; 35S, 35S promoter; Act 2, Arabidopsis actin 2 promoter; T, nos terminator; RdRp, RNA-dependent RNA
polymerase; Bars 1–8, introns; MP, TMV movement protein; 25K, 12K, 8K, PVX movement protein genes. B–E - Western blot analysis of purified PMT.
Purification of mAbs on protein A sepharose. Proteins were separated in a 10% polyacrylamide gel under non-reducing conditions (B, C) and in a 12%
gel under reducing conditions (D, E) and transferred to a PVDF membrane. Western blots: B and D were probed with gamma-chain-specific
antibodies; membranes C and E were incubated with kappa-chain-specific antibodies. 1–2, fractions from the protein A sepharose column; M, protein
molecular weight markers; S, standard - 20 ng hIgG. F - Capillary electrophoresis analysis of PMT in reducing conditions on Agilent 2100 Bioanalyzer.
Peak 12 corresponds to HC; peak 8 corresponds to LC. G, H – Comparison of PMT and trastuzumab. Proteins were separated in a 7.5% polyacrylamide
gel under non-reducing conditions (G) and in a 12% gel under reducing conditions (H) and stained with Coomassie blue. I - RP-HPLC trace analysis of
PMT and trastuzumab. The linear gradient was 0–60% acetonitrile for 20 min and then 60–100% acetonitrile for 5 min; the flow rate was 80 mL?min
21.
The buffer blank was 10 mM Na-phosphate (pH 7.0). Absorbance at 214 nm and 280 nm is shown.
doi:10.1371/journal.pone.0017541.g002
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There are two strategies of antibody engineering for plant
production [32]. First, one can employ antibody in miniaturized
format based on the observation that H chains retain some antigen-
binding capacity even in the absence of L chains. The smallest
format found to keep full binding activity is the so-called single-chain
fragment (scFv), in which the two variable regions, VH and VL, are
artificially linked by a flexible polypeptide [12–15]. The other
miniaturized type is the H-chain antibody derived from camelids
(camels and llamas) where the L chain is missing [33]. These
miniaturized antibodies do not require glycosylation and can be
assembled in both plant and prokaryotic systems such as Escherichia
coli. For example, scFv-based antibodies against HER2/neu have
been produced in E. coli and in plants using both stable and transient
systems in tobacco and Nicotiana benthamiana [12–15].
The second strategy is the creation of full-sized antibodies
because of their widespread use as anti-tumor agents [16–19] and
the fact that plants exhibit a similar endomembrane system and
secretory pathway compared to human cells [34]. Although
protein glycosylation in plant cells is slightly different from that of
animal cells [35], ‘‘humanized’’ N. benthamiana, Arabidopsis
thaliana, and Lemna minor plant lines have been generated [36–
38]. Many different forms of full-sized antibodies have been
produced in plant systems using either transient expression systems
or stable transgenic plants [16–20]. The latter strategy suffers from
generally low protein yields. In contrast, plant viral vectors
demonstrate a high potential to rapidly produce full-size
antibodies. In 2006, Giritch et al. [17] developed virus-based
Figure 3. Binding of PMT to a HER2/neu peptide mimotope.
Comparative binding of trastuzumab and PMT to the HER2/neu-specific
cyclic synthetic peptide 563CYC (CHPECQPQNGSVTCFGPEADQCVACA-
HYKDPPFCVA) [30]. Microtiter wells were coated overnight with 2 mg/ml
peptide and then blocked with 1% BSA for 1 h. The mAbs were then
added to plates at a concentration of 250 mg/ml and serially diluted 1:1
with phosphate buffered saline (PBS). Bound mAb was detected with
HRP-conjugated anti-human IgG and then with substrate.
doi:10.1371/journal.pone.0017541.g003
Figure 4. Examination of PMT binding to HER2/neu. Flow cytometry analysis of SK-BR-3 cells expressing HER2/neu incubated with
trastuzumab (A–C) and PMT (D–F) in the following concentrations: 10 mg/ml (A,D), 1 mg/ml (B,E), and 0.1 mg/ml (C,F). Cells incubated only with
secondary reagents were included as a control (open peak). Shadowed areas show specific binding. The percentage of cell surface expression of
HER2/neu in SK-BR-3 cells is shown. These data represent three separate experiments.
doi:10.1371/journal.pone.0017541.g004
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scalable production of full-size anticancer mAbs, creating an
opportunity for plant-made pharmaceuticals [22]. The above
system exploits pro-viral vectors and intron optimization of the
TMV vector in which putative cryptic splice sites were removed
and multiple plant introns were inserted [43,44]. Full mAb
production requires simultaneous expression of light- and heavy-
chain-encoding genes in the same plant cell infected with two
different non-competing viruses, such as TMV and PVX [17].
Here, we used 35S-based vectors and an assembled viral vector
system in which intron-optimized TMV and PVX vectors encoded the
heavy and light chains of PMT, respectively. Both viral and non-viral
systems directed production of PMT in N. benthamiana leaves; however,
high antibody production (100 to 150 mg/g FW) from non-replicating
vectors can be achieved only after TBSV p19 co-injection (Figure 1).
Joint injection of TMV and PVX vectors provided a yield of purified
antibody up to 300 mg/g FW and excluded the requirement of adding
an anti-silencing gene into the inoculation mixture.
Herceptin (trastuzumab) is a humanized mouse monoclonal
antibody 4D5 and binds to the domain IV of HER2 [29]. The precise
mechanisms underlying its action and acquired resistance are still
poorly understood. Recent studies have shown that Herceptin does not
decrease HER2 phosphorylation [45,46]. This failure to abolish HER2
phosphorylation may explain why acquired resistance inevitably occurs
for all patients if Herceptin is given as monotherapy [47].
Recently, Grohs et al. [19] used the magnICON system and
demonstrated that PMT produced in N. benthamiana inhibited the
growth of HER2-positive cancer cells. Functional assays revealed
that PMT and Herceptin have similar in vitro antiproliferative
effects on breast cancer cells that overexpress HER2. Here in line
with results of Grohs et al. [19], our experiments showed that
PMT efficiently suppressed SK-BR-3 cell growth in vitro.
Moreover, our purified PMT was as robust as trastuzumab in
recognizing the HER2/neu peptide mimotope (Figure 3) and
HER2/neu oncoprotein on the surface SK-BR-3 cells (Figure 4).
Surface plasmon resonance (SPR) spectroscopy is a potential
technique for the affinity profile identification of the molecules.
Although first SPR studies for trastuzumab were inconclusive [48],
further experimentation is needed to compare binding of these
antibodies to both the HER2/neu antigen and Fcc receptor.
Our direct testing of antitumor activity showed that PMT
efficiently retarded the growth of xenografted tumors derived from
human ovarian cancer SKOV3 Her2+ cells (Figure 6). Addition-
ally, PMT turned out to be more effective than trastuzumab in
suppression of tumor growth. The cause of this phenomenon is
unclear. SPR study may reveal differences in the affinity of
trastuzumab and PMT to the antigen and/or Fcc receptor, which
may help explain the enhanced tumour-restricting properties of
PMT in vivo. We suggest that it is too early to claim that PMT is
biosimilar to trastuzumab. Additional experiments are required to
prove that trastuzumab and PMT share full identity in their amino
acid sequence, glycosylation profile and ADCC.
Materials and Methods
Gene and vector engineering
The trastuzumab amino acid sequence (DrugBank accession
number DB00072) was used to synthesise the PMT light (LC) and
heavy (HC) chain genes. The Enthelechon backtranslation tool
(Markus Fischer, Backtranslation Tool, http://www.entelechon.
com/backtranslation, Entelechon GmbH, Regensburg, Germany)
was used for codon sequence determination.
35S-based vectors (35S-LC and 35S-HC) were made by
replacing the GFP-RFP cassette with LC or HC genes in a 35S-
GFP-RFP vector [49] using NcoI-XhoI sites.
The TMV-based vector was made in several cloning steps with
intermediate construct (IC) formation. A single, 1283 nucleotide EcoRI-
BamHI fragment from pICH4351 [43] was inserted into pGEM3Z to
create IC-1. To produce IC-2, two oligonucleotides (‘‘pl+’’ TCGA-
CAGCTAGCTCCATGGACTCGAGT and ‘‘pl2’’ GTACACTC-
GAGTCCATGGAGCTAGCTG) were annealed and inserted into
IC-1 using XhoI-BsrGI sites. Next, the HC gene was cloned into the
IC-2 digested with NcoI-XhoI, resulting in IC-3. In the final cloning
step, crucifer infected TMV (crTMV)-based vector with coat protein
(CP) fused with GFP gene (crTMV-CP-GFP) [50] was digested with
KpnI-BHI and used as a vector; the first fragment contained the
Figure 6. PMT inhibits tumor growth in a xenograft model of
human Her2+ ovarian cancer. The treatment groups received their
first doses (20 mg/kg) of PMT (n=7) and trastuzumab (n=10) in saline
solution i.p. 6 days after SKOV3 implantation, and then for 16 days, they
received 8 consecutive injections (10 mg/kg). The control group (n=34)
received saline solution. Tumor volumes were recorded in intervals 10–
14, 18–22 and 23–27 days after SKOV3 implantation using a caliper.
Data are the mean 6 standard deviations from two independent
experiments. Asterisk shows P,0.05 by the unpaired two tailed
Student’s t-test for statistical significance of difference between the
PMT and trastuzumab treatment and control.
doi:10.1371/journal.pone.0017541.g006
Figure 5. Effects of PMT on growth of the breast cancer cell line
SK-BR-3 in MTT assays. Growth inhibition effect of PMT compared to
trastuzumab (Herceptin, Hoffmann-La Roche) and rituximab (Hoffmann-
La Roche) as a negative control. This assay was repeated at least three
times.
doi:10.1371/journal.pone.0017541.g005
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polymerase (RdRp) with eight introns and a part of the TMV
movement protein gene were obtained from pICH17388 (courtesy of
Icon Genetics GmbH, and described in Giritch et al., 2006) [17] and
flanked with KpnI and EcoRI sites. IC-3 was digested with EcoRI and
BamHI, resulting in the second fragment. The TMV-HC vector was
achieved by ligation of these fragments.
Vector PVX-LC was made by modifying PVX-BIN19 [51]; the
CP gene was replaced with the LC coding sequence.
Agroinfiltration
Agrobacterium tumefaciens strain GV3101 was transformed with
individual binary constructs and grown at 28uC in LB medium
supplemented with rifampicin 50 mg/L, gentamycin 25 mg/L
and either carbencillin 50 mg/L or kanamycin 50 mg/L. An
aliquot of Agrobacterium cell suspension from an overnight culture
(2 ml) was diluted in 10 mM MES buffer (pH 5.5) supplemented
with 10 mM MgSO4 to a final OD600 of 0.3. Agroinfiltration was
performed on almost-fully-expanded N. benthamiana leaves still
attached to the intact plant. A bacterial suspension was infiltrated
into the leaf tissue using a 2-ml syringe, after which the plants were
grown under greenhouse conditions at 22uC with 16 hours of
light.
PMT extraction and purification
Total soluble protein was extracted from agroinoculated N.
benthamiana leaves with 10 mM sodium phosphate buffer. PMT
isolation from crude plant extract was performed with either
Protein A Sepharose
TM 4 Fast Flow (GE Healthcare) or 1 ml
HiTrap Protein A HP columns (GE Healthcare) according to
manufacturer’s protocol. A ‘‘Sartobind Q nano’’ membrane
(Sartorius Stedim Biotech) was used for further purification to
remove viruses, DNA and endotoxins.
HPLC equipment and conditions
HPLC analyses were performed on a narrow-bore column
(Milichrom A-02; EnviroChrom LC, Chromatography Institute
ECONOVA, Novosibirsk, Russia; 7562 mm) packed with 5-
lmparticles of Nucleosil C18, pore size 120 A ˚ (Macherey-Nagel,
Duren, Germany). Separations were performed at 25uC, and a
dual wavelength (214 nm and 280 nm) detector was used. The
elution gradient profile was as follows. The elution solvents were A
(0.1% trifluoroacetic acid in water, pH 2.2) and B (acetonitrile
with 0.1% trifluoroacetic acid). The linear gradient was 0–60% B
in 20 min and then 60–100% B in 5 min; the flow rate was
80 mL?min
21. Fractions were collected for subsequent analysis
using a Gilson 201 fraction collector.
SDS-PAGE, western blot analysis and ELISA
Samples (15 mg) of agroinfiltrated N. benthamiana leaves were
ground in the presence of celite in 50 ml of PBS. Crude leaf extracts
were resolved on 7.5 to 10% (non-reducing conditions) or 12%
(reducing conditions) polyacrylamide gels using Laemmli’s buffer
system[52] followed byCoomassie brilliant blueG-250staining.For
western blot analysis, fractionated proteins were transferred to a
Hybond-P PVDF membrane (GE Healthcare), blocked with 5%
skimmilk (Fluka) inTBS and probed with goat human-kappa-chain-
specificHRP-conjugated antibodies (Sigma)orgoat human-gamma-
chain-specific HRP-conjugated antibodies (Sigma) diluted 1:15,000
in TBS with 0.1% Tween 20. The western blot was developed with
an ECL detection reagent (GE Healthcare). The ELISA procedure
was described earlier [53].
Cell Proliferation Assay
The effect of anti-HER-2/neu mAbs on proliferation of the
human mammary adenocarcinoma cell line SK-BR-3 was
investigated by the MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-iphe-
nyltetrazolium bromide] assay as described [54], using saturating
mAb concentrations. Cells (1610
4 cells per well) were seeded in
96-well plates. After exposure to the different drugs for 48 h,
20 mL of MTT solution (5 mg/mL in PBS) was added to each
well, and the plates were incubated for an additional 4 h at 37uC.
The MTT solution in the medium was removed by aspiration. To
achieve solubilization of the formazan crystal formed in viable
cells, 150 mL of dimethylsulfoxide (DMSO) was added to each
well before absorbances (A) at 570 nm were measured. Cell
survival was calculated as the ratio of A570 nm in wells containing
a PMT compared to that in control wells with no PMT.
Nude mouse xenograft model of HER2+ SKOV3-derived
human ovarian cancer
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the N. N. Blokhin National Cancer
Research Center, Moscow, Russia. The protocol was approved by
the Committee on the Ethics of Animal Experiments of the N. N.
Blokhin National Cancer Research Center, Moscow, Russia
(Permit Number: 22, May 18, 2009). All surgery was performed
under sodium pentobarbital anesthesia, and all efforts were made
to minimize suffering.
Five million SKOV3 cells were s.c. injected into 4- to 6-wk-old
female BALB/athymic nude mice (Animal Center of N. N.
Blokhin National Cancer Research Center, Moscow, Russia). Six
days after SKOV3 implantation, when the average tumor volume
was 41615.5 mm
3, the treatment groups received their first dose
of PMT (20 mg/kg). Then for 16 days, the mice received 8
consecutive injections (10 mg/kg). The control group received
normal saline solution. Tumor volumes were recorded using a
caliper 10, 14, 18, 22, 23 and 27 days after SKOV3 implantation.
Supporting Information
Figure S1 Purification of PMT using protein A sephar-
ose. Proteins were separated in an 8% polyacrylamide gel under
non-reducing conditions (A) and in a 10% gel under reducing
conditions (B) and stained with Coomassie blue. Lanes 1–7,
fractions from the protein A sepharose column; lane 8, flow
through from the column; lane M, protein molecular weight
markers; lane S, standard - 1 mg hIgG.
(TIF)
Figure S2 Further PMT purification. H - PMT was purified
on an AKTApurifier (GE Healthcare) using 1 ml HiTrap Protein
A columns. Lanes 1–10, fractions from the protein A sepharose
column; lane 11, Sartobind Q nano purified protein. Protein
eluted from Sartobind with 1 M NaCl – lane 12.
(TIF)
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